Myriad Genetics (MYGN) Equity Average (2011 - 2026)

Myriad Genetics has disclosed Equity Average across 16 years of filings, most recently posting $352.7 million for Q1 2026.

• In Q1 2026, Equity Average fell 49.83% year-over-year to $352.7 million; the TTM figure through Mar 2026 stood at $352.7 million (down 49.83% YoY), while the FY2025 annual figure was $534.6 million, down 27.97% from the prior year.
• Equity Average fell to $352.7 million in Q1 2026, from $370.4 million in the prior quarter.
• Over the last five years, Equity Average for MYGN reached as high as $959.0 million in Q1 2022 and fell as low as $352.7 million in Q1 2026.
• The 5-year median for Equity Average is $736.1 million (2024), against an average of $715.1 million.
• Annual changes were most pronounced in 2022 — Equity Average increased 9.21% — and 2026, when it plunged 49.83%.
• A 5-year view of Equity Average shows it stood at $901.2 million in 2022, then declined by 18.63% to $733.3 million in 2023, then decreased by 2.3% to $716.4 million in 2024, then sank by 48.3% to $370.4 million in 2025, then slipped by 4.78% to $352.7 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $352.7 million, $370.4 million, and $380.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.